Publications by authors named "J Einck"
Article Synopsis
- - NIBB (Non-invasive Brachytherapy with Intrabeam) is a promising cancer treatment that offers targeted radiation with less damage to surrounding tissues compared to traditional methods, aiming to reduce treatment sessions from 10 to 5 for efficiency and cost-effectiveness.
- - In a clinical trial with 40 patients having small tumors and negative lymph nodes, the treatment showed excellent 5-year outcomes with 96.6% local control and minimal late toxicity (only 2.5% experienced significant fibrosis), while 75% of patients reported good to excellent cosmetic results.
- - The study concluded that NIBB APBI is effective and safe, with the risk of skin issues like telangiectasia linked to breast
Background: Physician explanation of gynecologic brachytherapy can be overwhelming or induce patient anxiety, and may be time-constrained given clinical limitations. We report the first randomized trial of an educational video intervention in gynecologic brachytherapy on patient-reported outcomes.
Methods: Between February 2020 and January 2022, 80 gynecologic cancer patients prescribed brachytherapy were randomly assigned to either standard informed consent (Arm A) or a supplemental 16 min brachytherapy educational video (https://vimeo.
Purpose: Shorter courses of breast radiotherapy are offered as an alternative to 4 weeks of whole-breast irradiation after lumpectomy, including brachytherapy. A prospective phase 2multi-institution clinical trial to study 3-fraction accelerated partial breast irradiation delivered by brachytherapy was conducted.
Methods And Materials: The trial treated selected breast cancers after breast-conserving surgery with brachytherapy applicators that delivered 22.
Purpose: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer.
Methods: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28..
Objective: To analyse the effect of age at diagnosis on clinical outcomes of localized prostate cancer (PCa) treated with radiation therapy.
Subjects And Methods: We identified 12 784 patients with intermediate- or high-risk localized PCa treated with radiation therapy (RT) and neoadjuvant androgen deprivation therapy (ADT) between 2000 and 2015 from nationwide Veterans Affairs data. Patients were grouped into three age categories (≤59, 60-69, and ≥70 years old).